Cargando…

Effects of Digoxin in Heart Failure (HF) With Reduced Ejection Fraction (EF)

In this review, we evaluated the literature on the benefits and deleterious effects of digoxin in heart failure (HF) with reduced ejection fraction (EF). Although digoxin was considered an effective treatment for HF, the supporting evidence is conflicting. Before the conventional use of modern HF th...

Descripción completa

Detalles Bibliográficos
Autores principales:	Parikh, Riya R, Patel, Khushbu R, Pergolizzi, Joseph V, Breve, Frank, Magnusson, Peter
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Cureus 2022
Materias:	Cardiology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8971068/ https://www.ncbi.nlm.nih.gov/pubmed/35371861 http://dx.doi.org/10.7759/cureus.22778

Ejemplares similares

The Use of Monoclonal Antibody-Based Proprotein Convertase Subtilisin-Kexin Type 9 (PCSK9) Inhibitors in the Treatment of Hypercholesterolemia
por: Parikh, Riya R, et al.
Publicado: (2022)

Deciphering the Dilemma: Anticoagulation for Heart Failure With Preserved Ejection Fraction (HFpEF)
por: Jyotsna, FNU, et al.
Publicado: (2023)

Digoxin is associated with worse outcomes in patients with heart failure with reduced ejection fraction
por: Zhou, Jingmin, et al.
Publicado: (2020)

Role of Ivabradine in Patients with Heart Failure with Preserved Ejection Fraction
por: Nadeem, Muhammad, et al.
Publicado: (2020)

Assessment of the Safety, Efficacy, and Benefit of Empagliflozin in Patients With Type 2 Diabetes Mellitus (T2DM) and Heart Failure With Reduced Ejection Fraction (HFrEF) at High Risk for Cardiovascular Events
por: Towiargi, Ruba, et al.
Publicado: (2022)

A Systematic Review Exploring the Cardiovascular and Renal Effects of Empagliflozin in Patients With Heart Failure With Reduced Ejection Fraction
por: Athiyaman, Sreekartthik, et al.
Publicado: (2022)

The Effect of Sacubitril-Valsartan on Ventricular Arrhythmia Burden in Patients With Heart Failure With Reduced Ejection Fraction
por: Medeiros, Paulo, et al.
Publicado: (2023)

Heart Failure with Preserved Ejection Fraction: Can Device Therapy Be Our Option?
por: Ahmed, Talha
Publicado: (2020)

Management of Heart Failure With Preserved Ejection Fraction in Elderly Patients: Effectiveness and Safety
por: Elkammash, Amr, et al.
Publicado: (2023)

Digoxin use in contemporary heart failure with reduced ejection fraction: an analysis from the Swedish Heart Failure Registry
por: Kapelios, Chris J, et al.
Publicado: (2021)

Heart Failure with Reduced Ejection Fraction (HFrEF) and Preserved Ejection Fraction (HFpEF): The Diagnostic Value of Circulating MicroRNAs
por: Chen, Yei-Tsung, et al.
Publicado: (2019)

The Role of Prognostic Nutrition Index in Predicting Hospitalization of Patients With Heart Failure With Mildly Reduced Ejection Fraction
por: Yurdam, Ferhat S, et al.
Publicado: (2022)

Inspiratory Muscle Training in Patients With Heart Failure With Preserved Ejection Fraction: A Meta-Analysis
por: Baral, Nischit, et al.
Publicado: (2020)

Cocaethylene: When Cocaine and Alcohol Are Taken Together
por: Pergolizzi, Joseph, et al.
Publicado: (2022)

Role of Diabetes Mellitus in Heart Failure With Preserved Ejection Fraction: A Review Article
por: Mgbemena, Okechukwu, et al.
Publicado: (2021)

A Case of Digoxin Toxicity Due to Acute Renal Failure
por: Digiovanni-Kinsley, Stephanie, et al.
Publicado: (2021)

Corrigendum to: Digoxin use in contemporary heart failure with reduced ejection fraction: An analysis from the Swedish Heart Failure Registry
Publicado: (2023)

Fibrin Sheath Catheter-Related Endovascular Right-Sided Heart Infection in Heart Failure With Reduced Ejection Fraction: A Case Report
por: Chambi-Torres, Javier B, et al.
Publicado: (2023)

Association of Major Depressive Disorder on Heart Failure With Reduced and Preserved Ejection Fraction: Analysis of National Readmission Database 2018
por: Thyagaturu, Harshith S, et al.
Publicado: (2021)

The Impact of Cocaine Use and the Obesity Paradox in Patients With Heart Failure With Reduced Ejection Fraction Due to Non-ischemic Cardiomyopathy
por: Akinlonu, Adedoyin A, et al.
Publicado: (2023)

Chronic Digoxin Toxicity: An Evaluation of Digoxin-Specific Antibodies and Other Management Options
por: Clifford, Liam M, et al.
Publicado: (2023)

Large Animal Models of Heart Failure With Reduced Ejection Fraction (HFrEF)
por: Spannbauer, Andreas, et al.
Publicado: (2019)

Pharmacotherapies in Heart Failure With Preserved Ejection Fraction: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
por: Baral, Nischit, et al.
Publicado: (2021)

Impact of Digoxin Use on Guideline-Directed Medical Therapy in Patients With Heart Failure With Reduced Ejection Fraction
por: Jabri, Ahmad, et al.
Publicado: (2022)

Improving risk stratification in heart failure with preserved ejection fraction by combining two validated risk scores
por: Boralkar, Kalyani Anil, et al.
Publicado: (2019)

The Value of Neutrophil-to-Lymphocyte Ratio and Epicardial Adipose Tissue Thickness in Heart Failure With Preserved Ejection Fraction
por: Colluoglu, Tugce, et al.
Publicado: (2023)

Comparison of Efficacy and Safety of Angiotensin Receptor-Neprilysin Inhibitors in Patients With Heart Failure With Reduced Ejection Fraction: A Meta-Analysis
por: Haseeb, Muhammad Talha, et al.
Publicado: (2023)

The Dilemma of Use of Anticoagulation in Patients With Heart Failure With Reduced Ejection Fraction and Sinus Rhythm: A Case Report and Literature Review
por: Haseeb ul Rasool, Muhammad, et al.
Publicado: (2023)

Heart failure with preserved ejection fraction (HFpEF): Implications for the anesthesiologists
por: Singh, Ajmer, et al.
Publicado: (2018)

Ischemic and non-ischemic patterns of late gadolinium enhancement in heart failure with reduced ejection fraction
por: Matusik, Patrycja S., et al.
Publicado: (2021)

QRS duration and cardiovascular mortality in Asian patients with heart failure and preserved and reduced ejection fraction
por: Yap, Jonathan, et al.
Publicado: (2021)

Dapagliflozin and Recurrent Heart Failure Hospitalizations in Heart Failure With Reduced Ejection Fraction: An Analysis of DAPA-HF
por: Jhund, Pardeep S., et al.
Publicado: (2021)

A Case of Significant Improvement of Heart Failure With Reduced Ejection Fraction With a Small Dose of Candesartan in a Hemodialysis Patient With Hypertensive Heart Disease and Nephrosclerosis
por: Harada, Haruhito, et al.
Publicado: (2023)

Isolated Left Ventricular Noncompaction Presenting With Heart Failure With Reduced Ejection Fraction and Intrahospital Cardiac Arrest: A Case Report and Literature Review
por: Gonçalves, Filipa Madalena F, et al.
Publicado: (2022)

Dapagliflozin and Diuretic Use in Patients With Heart Failure and Reduced Ejection Fraction in DAPA-HF
por: Jackson, Alice M., et al.
Publicado: (2020)

Effects of Dapagliflozin in Asian Patients With Heart Failure and Reduced Ejection Fraction in DAPA-HF
por: Docherty, Kieran F., et al.
Publicado: (2022)

Tubulin expression and modification in heart failure with preserved ejection fraction (HFpEF)
por: Schulz, Lisa, et al.
Publicado: (2022)

Proteomic and phosphoproteomic profiling in heart failure with preserved ejection fraction (HFpEF)
por: Valero-Muñoz, María, et al.
Publicado: (2022)

Isolated Flailed P3 Scallop of the Mitral Valve Leaflet in the Setting of Newly Diagnosed Heart Failure With Preserved Ejection Fraction
por: Salas Noain, Jesus, et al.
Publicado: (2020)

Worse In-Hospital Outcomes Among Patients With Heart Failure (HF) and Concomitant Influenza Infection
por: Torres, Andrea, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_2ufjlj1qmjrcs5oodbr5t3vo8d